Novopyxis

Biotechnology ResearchMassachusetts, United States2-10 Employees

Novopyxis is a Cambridge, Massachusetts-based biotechnology research company focused on developing therapeutics and medical devices. Its flagship therapeutic was developed in-house using proprietary mathematical algorithms and has demonstrated activity across in vitro, ex vivo, and in vivo models, targeting the anti-inflammatory receptor AT2R with cardioprotective and neuroprotective effects. The FDA has granted an orphan designation for Pediatric Cardiomyopathy for this program. The company also originated Droplette, a device-focused spin-out that aims to deliver large molecules, DNA/RNA, and proteins through skin, tissue, and cells, and Droplette currently collaborates with Leo Pharma on dermatology device development. 
Novopyxis operates in the biotechnology research sector and has earned multiple industry recognitions, including programs such as MassCONNECT, Amgen Golden Ticket, and Mass Challenge. The organization combines drug development with technology aimed at medical device delivery, illustrating a dual focus on therapeutics and enabling technologies. Based in Cambridge, the company maintains a small team and pursues partnerships and spin-out ventures to advance its scientific agenda.

Sign up for free to view info

Email Format Employee directory